Therefore IL-1β is pursued as a clinical target (for example, Canakinumab [24], which is used for treating autoinflammatory syndromes and in clinical trial for chronic obstructive pulmonary disease). The gene discussed is IL1B; the disease is chronic obstructive pulmonary disease.